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Abstract
Objective—Fragile X syndrome (FXS) and tuberous sclerosis (TSC) are genetic disorders that 
result in intellectual disability and an increased prevalence of autism spectrum disorders (ASD). 
While the clinical presentation of each disorder is distinct, the molecular causes are linked to a 
disruption in the mTORC1 (mammalian Target of Rapamycin Complex 1) and ERK1/2 
(Extracellular signal-Regulated Kinase) signaling pathways.
Methods—We assessed the clinical and molecular characteristics of an individual seen at the UC 
Davis MIND Institute with a diagnosis of FXS and TSC. Clinical evaluation of physical, 
behavioral, and cognitive impairments were performed. Additionally, total and phosphorylated 
proteins along the mTORC1 and ERK1/2 pathways were measured in primary fibroblast cell lines 
from the proband.
Results—In this case the phenotypic effects that result in a human with both FXS and TSC are 
shown to be severe. Changes in mTORC1 and ERK1/2 signaling proteins and global protein 
synthesis were not found to be noticeably different between four cohorts (typically developing, 
FMR1 full mutation, FMR1 full mutation and TSC1 loss of function mutation, and TSC1 loss of 
function mutation); however cohort sizes prevented stringent comparisons.
Conclusion—It has previously been suggested that disruption of the mTORC1 pathway was 
reciprocal in TSC and FXS double knock-out mouse models so that the regulation of these 
pathways were more similar to wild-type mice compared to mice harboring a Fmr1−/y or Tsc2−/+ 
mutation alone. However, in this first reported case of a human with a diagnosis of both FXS and 
TSC, substantial clinical impairments, as a result of these two disorders were observed. 
Differences in the mTORC and ERK1/2 pathways were not clearly established when compared 
between individuals with either disorder, or both.
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Introduction
Fragile X syndrome
Fragile X syndrome (FXS) is a neurodevelopmental disorder that is caused by a mutation in 
the fragile X mental retardation 1 (FMR1) gene. Typically, phenotypic severity is greater in 
males with FXS compared to their female counterparts [1]. Approximately 1 in 5000 males 
and 1 in 2500 to 1 in 8000 females have FXS [2]. Individuals with FXS can suffer from an 
array of behavioral, cognitive, neurologic, and physical problems, with core symptoms 
including intellectual disability, facial dysmorphia, macroorchidism, and mood disorders [3].
FXS occurs when the FMR1 gene is silenced by hyper methylation of the expanded 
trinucleotide repeat in the 5′UTR or a loss of function mutation, resulting in the absence of 
the encoded protein, FMRP [4,5]. The lack of FMRP, an RNA binding protein linked to 
translational control [6,7] results in increased translation of many mRNA targets at the 
synapse where it plays an important role for synaptic maturation, plasticity and function [8]. 
In 2004, the mGluR theory of FXS hypothesis proposed a specific example of how FMRP 
could play a role in the regulation of synaptic function and plasticity by regulating long-term 
depression (LTD) of synaptic strength in hippocampal neurons [9]. This form of LTD, 
involving stimulation of the metabotropic glutamate receptor 5 (mGluR5), requires protein 
synthesis. Accordingly, the psychiatric and neurological aspects of FXS may be the 
consequence of an exaggerated response to synaptic activation of the group 1 mGluRs that is 
coupled to local protein synthesis. The learning and memory deficits are proposed to occur 
through the over activation of two signaling pathways that control the synthesis of synaptic 
proteins, the mammalian Target Of Rapamycin Complex 1 (mTORC1) pathway and the 
Extracellular regulating kinase (ERK1/2) pathway [9,10]. The mTORC1 pathway is central 
to regulating protein synthesis, cell growth and proliferation and regulates Cap-dependent 
translation following inputs including growth factors, oxidative stress, and adequate energy 
and amino acid levels [11]. The ERK 1/2 signaling pathway controls the activity of the 
eukaryotic initiation factor 4E (eIF4E), a substrate that initiates translation by recruiting 
ribosomes to the 5′ mRNA cap. The ERK 1/2 signaling pathway is activated through 
extracellular inputs including mitogens and stress inducers [12]. Multiple studies have 
observed increased phosphorylation of mTOR targets in humans and mice with FMR1 
mutations in brain tissue and in peripheral blood cells and platelets when compared to 
tissues from typically developing controls or wild type mice [13,14,15,16,17]. Specifically, 
Sharma, Hoeffer et al. [15] reported that mTOR signaling is upregulated in the KO mouse 
model of FXS and increased expression of the eukaryotic initiation factor complex 4F 
(eIF4F). The dysregulation of the mTOR signaling observed in the FXS mouse model was 
also observed in human subjects with FXS where an increased phosphorylation of P70 S6K1 
(Thr389), ribosomal protein S6 (Ser235/236), Akt (Ser473), and eIF4E (Ser209) was 
detected in brain and PBMCs of individuals with FXS compared to control samples, 
suggesting increased translational activity also in peripheral cells. Recently, increased 
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translational activity and phosphorylation of mTOR (Ser2448), ERK1/2 (Thr202/Tyr204), 
and P70 S6K1 (Thr389) were also reported in primary cultured fibroblast cell lines [17].
Tuberous sclerosis complex
Tuberous Sclerosis Complex (TSC) is a genetic disorder that results in the formation of 
noninvasive lesions within numerous tissues and organs known as hamartomas. Variations in 
the size and number of lesions present lead to a broad range of clinical manifestations. In the 
85% of individuals with hamartomas within the central nervous system, cognitive 
impairments, behavioral problems and increased risk of epilepsy are common [18]. 
Estimated incidence rates for TSC is 1 in 6000 [19].
The genetic cause of TSC is the presence of a heterozygous loss of function mutation in 
either the tuberous sclerosis 1 (TSC1) gene on chromosome 9 or the tuberous sclerosis 2 
(TSC2) gene on chromosome 16. The proteins encoded by TSC1 (hamartin) and TSC2 
(tuberin) normally form a complex that regulates the mTORC1 signaling pathway directly 
through inhibition of the mTOR activator rheb (ras homologue expressed in brain) [20]. 
Therefore, the presence of loss of function mutations in either TSC1 or TSC2 results in 
increased mTORC1 activity [21,22] and subsequent increased phosphorylation of S6K1 and 
4EBP1, the two downstream effectors of translation [23]. Substrates along the mTORC1 
pathway including P70 S6K1 and ribosomal protein S6 show increased phosphorylation in 
individuals with TSC and animal models [24]. Additionally, mice with heterozygous loss-of-
function mutations in TSC1 or TSC2 have reduced mGluR-LTD, decreased postsynaptic 
translation [25] and show learning and memory deficits, independently from a tumor or 
seizure phenotype [26].
Comorbidities across FXS and TSC
FXS and TSC are two closely associated genetic disorders. Both disorders have a high 
prevalence of intellectual disabilities, autism spectrum disorders (ASD) and seizures 
[27,28,29,30,31,32,33,34]. Interference with normal synaptic plasticity causes cognitive 
deficits in both syndromes and is suspected to be a core perturbation that increases the risk 
of developing autism [35,36].
The convergence of FXS and TSC pathophysiology on the mTORC1 signaling pathway 
suggests that understanding the similarities and differences in the mechanisms of these 
disorders could inform and lead to the development of targeted treatments. As such, a 
comparison of the pathophysiology in the Fmr1−/y mouse and Tsc2−/+ mouse was 
investigated [25]. The study reported a reduction in mGluR dependent LTD and protein 
synthesis in the Tsc2+/− mice compared to the exaggerated mGluR-LTD found in the 
Fmr1−/y mice [15,37]. The cross of these mice, Fmr1−/y Tsc2−/+ resulted in mGluR-LTD 
levels between mice with either mutation alone, and most similar to the WT mice. These 
double mutant mice had improved memory compared to the Fmr1−/y or Tsc2−/+ mice, 
suggesting the mutations altered mTORC1 signaling reciprocally and this balanced the 
activity of the pathway when both mutations were present. These results suggested a range 
of activity that is optimal for the translational signaling pathway, and deviation from that 
range either by increasing or decreasing the activity would result in pathology. Noticeably, 
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gene expression profiles showed significant difference between the Tsc2−/+ and Fmr1−/y 
mice, suggesting that cellular pathophysiology may be profoundly different in contrast to the 
similar phenotypic characteristics [38].
Interestingly, a unique case of a female with both FXS and TSC was clinically evaluated in 
the Fragile X Research Clinic at the UC Davis MIND Institute. Here we describe the clinical 
presentation of this participant as well as molecular consequences of the double genetic hit 
with respect to mTORC1 and ERK1/2 signaling in the derived fibroblast cell line from this 
patient and compare to those observed in subjects with the FMR1 full mutation alone and in 
a subject with a TSC1 loss of function mutation.
Methods
Participants
A total of 7 females: three typically developing controls, two harboring an FMR1 full 
mutation, one with both an FMR1 full mutation and a TSC1 loss of function mutation, and 
one with a TSC1 loss of function mutation (age range for 7 females=11–40 years) were 
included in this study. Participants were recruited following protocols approved by the 
Institutional Review Board at UC Davis and provided informed consent.
Establishing primary fibroblast cell lines
Explants of dermal biopsies (~ 3 mm) were minced and placed in a 100-mm TC-treated 
tissue culture dish (Corning Life Science) with 5 mL fibroblast medium (Gibco AmnioMax-
C100 Basal Medium with 15% AmnioMax-C100 Supplement (Invitrogen)) and placed in 
37°C humidity incubators with 5% CO2 atmosphere. Media was replaced every 3–4 days 
until fibroblast outgrowths from one explant were a quarter of the size of the dish. 
Fibroblasts were passaged into a new dish by trypsinization, and grown in modified 
fibroblast medium (1 part AmnioMax-C100 medium (as described above), 1 part 
RPMI-1640 medium (RPMI-1640 basal medium (Invitrogen) supplemented with 1X 
Primocin (Invivogen), 1% non-essential amino acids, and 10% fetal bovine serum (Corning 
Life Science)). Media was replaced every 3–4 days and allowed to reach 90% confluence 
prior to passaging. Fibroblast cultures were passaged between 2–20 times prior to collection 
for DNA, RNA, cryopreservation, or cell activation.
Cell activation
Primary fibroblasts were seeded in triplicate onto black walled clear bottom TC-treated 96 
well plates at 10,000 cells per well in modified fibroblast medium (as described above) 
overnight in a 37°C humidity incubator with 5% CO2 atmosphere. The following day media 
was replaced with serum-starvation media (RPMI-1640 basal medium supplemented with 
1X Primocin, 1% non-essential amnio-acids, and 0.5% Bovine Serum Albumin (Miltenyi 
Biotec)) and incubated overnight in the 37°C humidity incubator. The next day media was 
replaced with fresh serum-starve media and cells were stimulated with 25 ng/ml of platelet-
derived growth factor (PDGF) (Cell Signaling) or 20 ng/ml or phorbol 12-myristate 13-
acetate (PMA) (Tocris) for 5 minutes to 3 hours. or kept unstimulated. Cells were stimulated 
with PDGF in order to activate the mTOR signaling pathway through PI3 kinase, or PMA to 
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activate the ERK1/2 signaling pathway through protein kinase C, to measure 
phosphorylation of substrates along these pathways following activation. Following 
stimulation, fibroblast cells were fixed in 4% paraformaldehyde for 15 minutes at room 
temperature (RT) for in cell Western (ICW) assays, or washed two times with ice cold PBS 
and lysed in lysis buffer which consisted of 1X Cell Lysis Buffer (Millipore) supplemented 
with Protease Inhibitor Cocktail 1 (Sigma), Phosphatase Inhibitor Cocktail 2 (Sigma), and 
Phosphatase Inhibitor Cocktail 3 (Sigma).
In cell western
Following fixation, cells were permeabilized by five times washes in 0.1% Triton X-100 in 
1X Tris Buffered Saline (TBS). Cells were blocked for 1 hour at RT in Licor Blocking 
Buffer (Licor), and hybridized overnight at 4°C in primary antibody (1:250 phospho-eIF4E 
(Ser209) (Abcam), 1:300 phospho-Akt (Ser473) (Cell Signaling), 1:200 phospho-ERK1/2 
(Thr202/Tyr204) (Cell Signaling), 1:400 phospho-4EBP1 (Thr70) (Cell Signaling), 1:500 
phosphor-P70 (Thr389) (Cell Signaling), 1: 400 phosphor-S6 (Ser235/236) (Cell Signaling), 
and 1:400 phosphor-mTOR (Ser2448) (Cell Signaling)). Cells were washed 5 times in TBS 
with 0.1% Tween-20 and hybridized with 1:5000 Cell Tag (Licor) and 1:800 goat anti-
mouse 800CW (Licor) or donkey anti-rabbit 800CW (Licor) for 1 hour at RT. Cells were 
washed 5 times in TBS with 0.1% Tween-20 and a final wash in TBS. Liquid was decanted 
from the 96 well plate and the plate was scanned using the Odyssey Imager (Licor) and 
Image Studio (Licor). We compensated for differences in cell numbers by adjusting the 
phosphorylation levels (800 channel) by the Cell Tag signal (680 channel). Phosphorylation 
levels are reported as a ratio to the mean signal in the control cells.
Infrared western blotting
Standard methodologies were used. Between 5 and 30 μg of proteins were separated by 
SDS-PAGE and blotted onto PVDF membranes (Millipore). Membranes were blocked for 2 
hours in Licor Blocking Buffer and then hybridized overnight on 1:1000 primary antibodies. 
The following day membranes were washed 3 times in TBST (Bio-Rad) and hybridized with 
secondary antibody for 1 hour (1:50,000) (Licor). Membranes were washed in TBST with a 
final wash in TBS without Tween-20. Detection of immunoreactive bands, was performed 
by scanning the membranes using the Odyssey Imager following manufacturer’s 
recommendations. Band’s intensity was measured using Image Studio software.
Standard western blotting
Standard methodologies were used. Between 5–20 μg of total cell lysate were separated by 
SDS–PAGE electrophoresis and blotted on a PVDF membrane (Millipore). All the 
antibodies used in this study were commercially available except for FMRP (Ferrari et al. 
2007) 1:1000. Primary antibodies: GAPDH (Chemi-Con) 1:10000; p-mTOR (Ser 2448) and 
total mTOR (Cell Signaling) 1:1000, p-ERK1/2 and total ERK1/2 (Santa Cruz) 1:1000;. p-
AKT-P and total AKT (Cell Signaling) 1:1000; p-4E-BP1-P and total 4E-BP1 (Cell 
Signaling).1:1000. Proteins were revealed using an enhanced chemiluminescence kit (BIO-
RAD) and the imaging system LAS-3000 (Fuji). Quantification was performed using the 
AIDA software (Raytest, version 4.27) and Coomassie staining of the membranes.
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SUnSET
A protein synthesis assay was performed as previously described using the SUnSET method 
(Schmidt et al., 2009). Western Blot analyzed puromycin-treated samples and puromycin 
incorporation was detected using the mouse monoclonal antibody (1:5000, PMY-2A4 
DHSB). Coomassie staining of total proteins or immunolabeling of housekeeping proteins as 
GAPDH was used as loading controls.
CGG sizing and methylation status
CGG repeat allele size was determined by using both PCR and Southern Blot analysis as 
previously described [39,40]. Methylation status was assessed on the Southern blot by 
densitometry using the Alpha Innotech FluorChem 8800 Image Detection System. 
Methylation status included percent of methylation, indicating the percent of cells carrying a 
methylated allele and, the activation ratio, which indicate the fraction of cells carrying the 
normal allele on the active X chromosome. FMR1 mRNA expression levels measurements 
were performed by quantitative Real Time PCR; details are as in Tassone et al., [41].
Statistical analysis
To test whether the phosphorylation levels were significantly different in cells harboring an 
FMR1 full mutation or TSC1 mutation compared to control cells, Mann-Whitney tests were 
used, and p-values below 0.05 were reported as statistically significant.
Results
Female subject with heterozygous loss of function mutations in both FMR1 and TSC1: 
clinical history
The 12 year and 9 months old Caucasian female affected with both FXS and TSC was 
medically and clinically evaluated.
Dysmorphic facial features were noted including widely spaced eyes with epicanthal folds 
and a flattened nasal bridge, with midface flattening and mild mandibular prognthism. 
Possible aspects of adenoma sebaceum (facial angiofibroma) on her cheeks were present. 
The woods lamp exam showed the presence of a couple hypopigmented macules on the right 
lower leg, a couple of very small spots on her right hand, and a larger spot about 1 cm square 
on her lower back. Facial angiofibromas were also present as well as a left great toe ungula 
fibroma. These physical abnormalities support the diagnosis of tuberous sclerosis (Figure 1) 
[42]. Her neurosensory exam was normal as was her muscle strength. She was tanner at 
stage III, and her finger joints were hyperextensible with MP extension to 90 degrees.
She was adopted from Russia at 5.5 months of age, she was known to have a 34 week 
gestation with an Apgar score of 7 and 8 and a birth weight of 4 lbs. 6 oz. She was 
diagnosed with FXS during her first year. Her milestones included sitting at 9 months of age, 
walking at 16 months, saying words at 18 months and putting together words at 5 years of 
age. She had some speech regression at 18 months, coinciding with seizure episodes. She 
also had very low muscle tone and had difficulty maintaining an upright posture for a 
sustained period of time.
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She reportedly had frequent staring spells as an infant and at 18 months of age she became 
tonic and then had a generalized seizure. By 1 year 8 months of age she had 12 reported 
events of unusual motor movements diagnosed as seizures. These continued to 33 months of 
age, including febrile convulsions. She had up to 5 or 6 seizures per day with postictal 
sedation and hospitalized at 2 years and 9 months of age. Mesial frontal cortical dysplasia on 
the right side was shown on an MRI scan along with white matter signals in the centrum 
semiovale suggestive of possible ischemic changes. At this time she had an Early Learning 
Composite on the Mullen Scales of Early Learning of 50 (1st percentile). She had cystoscopy 
for recurrent urinary tract infections and adenoidectomy at 18 months of age.
When she was 7 years and 4 months of age she was diagnosed with cholelithiasis. She 
showed mood lability, particularly around her menses, which began at age 10. She had 
impulsivity, inattention, hyperactivity, gaze avoidance, tactile defensiveness, significant 
anxiety, and perseverative language. She has pronounced imitation skills that allow her to 
readily model the actions and words of people around her. She also exhibits hyperarousal to 
sensory stimuli, hyperactivity and selective mutism. Her speech is affected by verbal and 
oral dyspraxia, and she fit the diagnosis of moderate ASD by Autism Diagnostic 
Observation Scale (ADOS 2) when tested at 12 years and 5 months of age. She also has had 
a history of sleep problems.
At 6 years of age she began taking Daytrana (40 mg patch). Prior to Daytrana she was also 
prescribed topiramate, clonazepam, and Diastat. She has continued on Daytrana (40 mg per 
day) and guanfacine (1 mg three times per day), which is helping with her impulsivity and 
hyperarousal along with ADHD symptoms. She has tics including a blinking tic and 
shoulder shrugs but they disappeared on the guanfacine. She was without seizures for several 
years but they reoccurred at age 12 and her anticonvulsant medication was changed to 
oxicarbamazepine and she currently has only one seizure a year. Her most recent MRI at age 
15 demonstrated multiple tubers frontally and a tuber on each side of the Foraman of Munro 
but they are not blocking CSF flow.
Her non-pharmacological treatments have included special education intervention in school 
in addition to physical therapy, occupational therapy and speech and language therapy on a 
weekly basis. She has also utilized the CogMed program, a digital program through the 
internet to improve attention and concentration.
DNA molecular testing
Clinical testing of whole exome sequencing detected a 4 bp deletion in TSC1 resulting in a 
frame-shift loss of function mutation. Fragile X DNA testing also revealed the presence of 
the FMR1 full mutation (570, 710, 1050 CGG repeats), and of a normal allele of 29 CGG 
repeats, with an activation ratio of 0.68. DNA testing in fibroblast cells derived from this 
female revealed the presence of the same normal and methylated full mutation alleles with 
an activation ratio of 0.3. She had lower FMR1 mRNA (0.61 ± 0.10) and lower FMRP 
(0.031) expression levels than typically developing controls (FMR1 mRNA in controls=1.42 
± 0.26, and FMRP levels in ERK 1/2 controls=1.2 ± 0.02 [41,43].
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Regulation of the mTORC1 and ERK pathways not significantly altered in fibroblast cells 
harboring FMR1 and TSC2 mutations
The dysregulation of the pathways controlling protein synthesis is one of the hallmarks of a 
number of neuropsychiatric disorders [44]. A dysregulation of protein synthesis have been 
observed in FXS mice [45,46,47,48] and recently have been also reported in primary cells 
(fibroblasts) as well as in lymphoblastoid cell lines derived from patients with FXS [17,48]. 
Recent experiments showed in a mouse model for Tuberous sclerosis showed an 
amelioration of the dysregulated pathways in FXS [25]. We investigated protein synthesis 
activity in fibroblasts from the proband with the double FMR1/TSC1 mutation, three 
females without FMR1 or TSC1 mutations, 2 females with FMR1 mutations, and 1 female 
with a TSC1 loss of function mutation using SUnSET technology, a non-radioactive assay 
for labeling newly synthesized proteins [49].
Newly synthesized proteins were measured by puromycin incorporation. No significant 
difference in protein synthesis was shown between the four genotypic groups, though small 
increased protein synthesis was observed in the FXS cohort compared to the other three 
cohorts. While our findings suggest that the double mutation might indeed normalize the 
excessive protein synthesis in FXS, the statistical significance of these data were limited by 
the fact that the fibroblast cell line derived from the FXS & TSC patient represents a unique 
human case harboring both FMR1 and TSC1 mutations (compared in this study with the 
matched controls harboring FMR1 or TSC1 mutation) (Figure 2).
Next, we assessed the phosphorylation levels of a number of proteins along the mTORC1 
and ERK1/2 signaling pathways, regulators of protein synthesis, in fibroblast cells from the 
four cohorts. Phosphorylation and total protein levels were measured using both In Cell 
Western assays and Western blots for ERK 1/2, Akt, mTOR, P70 S6K1, eIF4E, 4E-BP, and 
ribosomal protein S6.
Although for all proteins analyzed, the double mutation showed a tendency to a decreased 
phosphorylation status, no significant differences were observed (Figure 3).
Furthermore, fibroblast cells were stimulated with PDGF or PMA, or unstimulated prior to 
measuring mTORC1 and ERK1/2 activity. Mann-Whitney tests compared females in the TD 
cohort and females in the FXS cohort including the proband for each time point. No major 
differences were observed in the phosphorylation of ERK 1/2 (p>0.3), Akt (p>0.4), mTOR 
(p>0.2), p70 S6K1 (p>0.7), eIF4E (p>0.1), 4EBP (p>0.4) or RP-S6 (p>0.2) (Supplementary 
figure 1).. Detection of differences in the protein and phosphorylation levels of these data 
were limited by the cohort sizes, the uniqueness of the human case where no other patient is 
known to exist, and the FMRP expression levels of females harboring an FMR1 full 
mutation are highly variable. However, we did not observe pronounced differences between 
any of our cohorts.
Discussion
While mTORC1 and ERK1/2 signaling dysregulation was not detected in the primary 
cultured fibroblast cells, the clinical evaluation of the proband harboring both the FMR1 full 
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mutation and TSC1 loss of function mutation showed pronounced deficits in learning, 
behavior and, typical physical disease features of FXS and NF1, but the severity of her 
problems were more severe than what is typically seen in females with FXS. Females with 
the FMR1 full mutation are typically less severely affected than their male counterparts, in 
large part due to the X-inactivation that randomly silences either the full mutation or normal 
FMR1 allele in females. As such, FMRP expression in females with FXS is commonly 
observed at a higher level than in affected males, and these higher levels can be beneficial 
[43].
A FXS-TSC “double-hit” mouse model has previously been reported, which showed 
remarkably improved phenotype compared to mouse models of FXS or TSC [26]. Although 
the proband described here presents with a severe phenotype compared to typical females 
with a FXS diagnosis, however it is unclear if this is due to the type of TSC mutation, the 
variability in FMRP expression levels seen in females, or species differences. The proband 
presented with a loss of function mutation in TSC1, such mutations are predicted to have a 
lower severity than TSC2 loss of function mutations, modeled in the “double-hit” mouse. It 
is therefore difficult to compare the biological effect of this double mutation genetic 
background with what has been observed in the Fmr1 (−/y) Tsc2 (−/+) mouse [25] however 
we did not observe a less severe clinical presentation.
In conclusion, this study demonstrates the level of complexity underlying how these 
mutations alter the regulation of both the mTORC1 and ERK1/2 signaling pathways in 
human tissue and cells. Understanding these complexities is of importance for developing 
treatments for both FXS and TSC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Patient with FMR1 and TSC1 mutations. A) Note the long face and prominent ears. B) Skin 
macules seen with Woods lamp. C) White skin macules seen on hand.
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Figure 2. 
Protein synthesis was not significantly different between cohorts in fibroblast cells. A) Left 
upper panel shows a representative WB of cells treated with puromycin and stained with 
antibodies against puromycin. Left lower panel shows the same blot stained with coomassie 
used as loading control. Right panels, levels of protein synthesis obtained normalizing the 
puromycin signal to the Coomassie staining. Bars represent the mean + Standard Error (n = 
3), FXS (n = 2), TSC (n = 1), TSC&FXS (n = 1) technical triplicates). B) Left panel, 
representative WB images for FMRP from cells from controls (TD), FXS, TSC and 
TSC&FXS patients. Right panel, quantification of FMRP normalized to GAPDH. Bars 
represent the mean + Standard Error (n = 3), FXS (n = 2), TSC (n = 1), TSC&FXS (n = 1) 
technical triplicates).
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Figure 3. 
Phosphorylation of substrates along the mTORC1 and ERK1/2 signaling pathways were not 
significantly different between cohorts in fibroblast cells. Left panels, representative WB 
images for mTOR, p-mTOR, ERK-1/2, p-ERK-1/2, FMRP, AKT, p-AKT, 4-EBP1, 
p-4EBP1, rpS6, eIF4E, p-p70, GAPDH (loading control), and coomassie stain from 
fibroblast lysates of controls (TD, n = 3), FXS (n = 2), TSC (n = 1), TSC&FXS (n = 1). 
Right panels, quantification of phosphoproteins levels over total normalized to GAPDH. 
Mean of technical duplicates is represented.
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